A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction

Trial Profile

A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs Lubiprostone (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 04 Sep 2013 Data will be presented during PAINWeek 2013, according to a Sucampo Pharmaceuticals media release.
    • 01 May 2013 New trial record
    • 23 Apr 2013 FDA approved sNDA for lubiprostone for opioid-induced constipation in adults with chronic, non-cancer pain based on results of OPAL trials and long-term safety study, according to a media release from Sucampo Pharmaceuticals and Takeda Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top